News

Press Releases

  • 11
    Dec. 2017
    Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

    — Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers — — Preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer — JERUSALEM and CAMBRIDGE, Mass., December 11, 2017 – Gamida Cell, a leading cellular […]

  • 20
    Nov. 2017
    Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

    Biotech leader to further advance promising pipeline, including breakthrough therapy, NiCord®, in phase 3 development as a universal bone marrow transplant solution JERUSALEM, Israel and CAMBRIDGE, Mass., November 20, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer. Dr. […]

  • 1
    Nov. 2017
    Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

    Phase 2 NiCord Data in Allogeneic Bone Marrow Transplant and Preclinical Data for NK Cells to be Presented in Oral Presentations JERUSALEM, Israel, November 1, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that two oral presentations on new data from the company’s pipeline programs will be presented during the […]

  • 26
    Sep. 2017
    Gamida Cell World Cord Blood Day Conference, November 15, 2017

    Advisory Event: Gamida Cell World Cord Blood Day Conference This conference will present the newest research in cord blood expansion for cellular and immune treatment of cancer and orphan genetic diseases. Date: November 15, 2017 Location:  Gamida Cell, Beit Ofer, 5 Nahum Hafzadi Street, Jerusalem, ISRAEL. This event is open to the general public. Contact: kelly@gamida-cell.com […]

  • 21
    Aug. 2017
    Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

    This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI) Jerusalem, Israel, August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. […]

  • 20
    Jul. 2017
    Gamida Cell Announces $3.5 Million Grant from the Israeli Government

    Non-dilutive funding follows the recent closing of a $40 million round Combined financing will support further development and commercialization of NiCord®, a breakthrough designation product for blood cancers Jerusalem, Israel, July 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that […]

  • 10
    Jul. 2017
    Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

    Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join […]

  • 19
    Jun. 2017
    Gamida Cell Announces $40 Million Private Financing

    Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers Jerusalem, Israel, June 19, 2017 — Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the signing of a $40 million financing to […]

  • 5
    Jun. 2017
    Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors

    Professor Kornberg brings to Gamida Cell a celebrated expertise in scientific discovery and therapeutic development Dr. Perry brings deep R&D expertise in cell and gene therapy and decades of experience successfully guiding private and publicly traded companies Jerusalem, Israel, June 5, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment […]

  • 20
    Apr. 2017
    Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation

    NiCord-transplanted patients demonstrated improvements in time to engraftment, bacterial and non-viral grade 2-3 infection rate, and duration of hospitalization  Jerusalem, Israel, April 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today the publication of positive clinical outcomes from an investigator-initiated study […]

Write to Us